Isotechnika Inc. granted patent for mTOR inhibitor



    EDMONTON, Dec. 5 /CNW/ - Isotechnika Inc. announced today that the
process of nationalizing European Patent No. 1644392 has commenced with the
issuance of a Swedish Patent for its mTOR inhibitor, TAFA93. In accordance
with the European Patent Convention, this patent will be granted in a total of
31 European countries of which patents for the remaining 30 countries will be
forthcoming.
    "Our medical device partnership with Atrium Medical makes use of TAFA93
on Atrium's drug eluting stent technology," stated Dr. Robert Foster,
Isotechnika's Chairman & CEO. "This allows us to broaden our product pipeline
while maintaining our primary focus in transplantation."

    About TAFA93
    ------------
    The Company's second drug in development is TAFA93, an advanced pro-drug
of rapamycin. TAFA93 is a novel small molecule mTOR inhibitor, which is a
class of drugs currently used in the prevention of organ rejection in
transplantation. mTOR inhibitors are typically used in combination with
calcineurin inhibitors after organ transplant. These anti-proliferative mTOR
inhibitors also have utility in oncology and as drug coating for coronary
stents and surgical meshes. The drug-eluting stent market was estimated at
$5.5B in 2005. TAFA93 has successfully completed Phase 1 clinical trials.

    About Isotechnika
    -----------------
    Edmonton-based Isotechnika Inc. is an international biopharmaceutical
company focused on the discovery and development of novel immunosuppressive
therapeutics that are designed to offer advantages over other currently
available treatments. There is a significant unmet medical need in the
treatment of both solid organ transplantation and autoimmune disease. It is
estimated that the market potential exceeds $2 billion annually in sales for
calcineurin inhibitors such as ISA247.
    ISA247 is currently being investigated in a Phase 2b North American trial
for the prevention of kidney graft rejection subsequent to transplantation and
a Phase 3 European/Canadian psoriasis trial.
    Isotechnika Inc. is a publicly traded company on the Toronto Stock
Exchange under the symbol "ISA". More information on Isotechnika can be found
at www.isotechnika.com.

    Partnerships with Isotechnika Inc.
    ----------------------------------

    
    -   Roche retains an option to continue development of the transplant
        indications based on the successful completion of the ongoing
        Phase 2b kidney transplant trial.

    -   Atrium Medical Corporation has exclusive worldwide licensing
        agreement for use of ISA247 and TAFA93 with drug eluting devices for
        non-systemic treatment of vascular, cardiovascular, target vessel and
        issue disorders.

    -   Lux Biosciences Inc. was granted worldwide rights to develop and
        commercialize ISA247 for the treatment and prophylaxis of all
        ophthalmic diseases.
    

    Forward-Looking Statements
    --------------------------
    This press release may contain forward-looking statements. Forward
looking statements, including the Company's belief as to the potential of its
products, the Company's expectations regarding the issuance of additional
patents and the Company's ability to protect its intellectual property,
involve known and unknown risks and uncertainties, which could cause the
Company's actual results to differ materially from those in the forward
looking statements. Such risks and uncertainties include, among others, the
availability of funds and resources to pursue research and development
projects, the ability to economically manufacture its products, the potential
of its products, the success and timely completion of clinical studies and
trials, the Company's ability to successfully commercialize its products, the
ability of the Company to defend its patents from infringement by third
parties, and the risk that the Company's patents may be subsequently shown to
be invalid or infringe the patents of others. Investors should consult the
Company's quarterly and annual filings with the Canadian commissions for
additional information on risks and uncertainties relating to the
forward-looking statements. Investors are cautioned against placing undue
reliance on forward-looking statements.

    %SEDAR: 00010508E




For further information:

For further information: Dr. Robert Foster, Chairman & CEO, Isotechnika
Inc., Phone: (780) 487-1600 (x247), Fax: (780) 484-4105, E-mail:
rfoster@isotechnika.com; Stephanie Gillis-Paulgaard, Director, Corporate
Communications, Isotechnika Inc., Phone: (780) 487-1600 (x243), Fax: (780)
484-4105, E-mail: sgillis-paulgaard@isotechnika.com

Organization Profile

ISOTECHNIKA PHARMA INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890